JY-2
Based on 3 publication(s) in Google Scholar
JY-2 is a moderately selective and orally active Forkhead transcription factor forkhead box O1 (FoxO1) inhibitor that inhibits FoxO1 transcriptional activity with an IC50 of 22 μM. JY-2 shows moderate inhibition against FoxO3a and FoxO4. JY-2 shows anti-diabetic activity.
For research use only. We do not sell to patients.
- Purity : 99.75%
- CAS No.: 339103-05-8
- Formula: C13H7Cl2N3O
- Molecular Weight:292.12
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) JY-2
More
Customer Validation & Images
-
Cell Imaging/Staining
-
Bio/Physico-chemical Assay
-
Cell Imaging/Staining
-
WB
-
Cell Proliferation/Viability Assay
Biological Activity
Description
IC50 & Target
22 μM (FoxO1 transcriptional activity)[1]
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
1.7 μM
Compound: 7f
|
Negative allosteric modulation of human recombinant mGluR5 expressed in HEK293 cells expressing GLAST assessed as inhibition of DHPG-induced intracellular Ca2+ level after 30 mins by FLIPR assay
Negative allosteric modulation of human recombinant mGluR5 expressed in HEK293 cells expressing GLAST assessed as inhibition of DHPG-induced intracellular Ca2+ level after 30 mins by FLIPR assay
|
[PMID: 23046966] |
In Vitro
JY-2 (10-100 μM; 24 h) reduces palmitic acid (PA; HY-N0830)-induced lipotoxicity in HepG2 and INS-1 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HepG2 and INS-1 cells
-
Concentration:10, 50 and 100 μM
-
Incubation Time:24 h
-
Result:Reduced palmitic acid (PA)-induced G6Pase and PEPCK mRNA expression. Inhibited PA-induced lipid accumulation. Reduced PA-induced mRNA expression of ER stress markers (ATF3, CHOP and GRP78).
-
Cell Line:HepG2 cells
-
Concentration:10, 50 and 100 μM
-
Incubation Time:4 h; in the presence of PA (500μM)
-
Result:Increased p-FoxO1 levels in the whole cell lysate with a concurrent reduction in nuclear FoxO1 levels.
In Vivo
Pharmacokinetic parameters of JY-2[1]
| Parameters | i.v. (20 mg/kg) | p.o. (50 mg/kg) |
| AUCall (ng·h/mL) | 5017 ± 1038 | 12270 ± 2775 |
| AUCinf.obs (ng·h/mL) | 5030 ± 1037 | 12400 ± 2753 |
| Cmax (ng/mL) | 10790 ± 3269 | 6826 ± 2342 |
| Tmax (h) | 0.1 ± 0.1 | 0.8 ± 0.7 |
| T1/2 (h) | 0.8 ± 0.2 | 1.3 ± 0.4 |
| MRTinf.obs (h) | 0.7 ± 0.1 | 2.0 ± 0.1 |
| F (%) | 97.8 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mice[1]
-
Dosage:50, 100, 200 mg/kg
-
Administration:Oral, three times for two days (9:00 AM, 7:00 PM, 9:00 AM on the next day)
-
Result:Improved glucose tolerance. Significantly reduced the expression of G6Pase and PEPCK mRNA in the liver. Enhanced mRNA expression of insulin and PDX-1 in the pancreas.
-
Animal Model:db/db mice and C57BL/6J mice, high fat-diet-induced obese diabetic (DIO) model[1]
-
Dosage:50, 100 mg/kg
-
Administration:Oral, once daily for 4 weeks
-
Result:Decreased the levels of fasting blood glucose, improved glucose tolerance. The expression of ColIV, a fibrosis marker, was also lowered.
-
Animal Model:C57BL/6J mice[1]
-
Dosage:20 mg/kg or 50 mg/kg
-
Administration:IV or PO (Pharmacokinetic Analysis)
-
Result:Showed an overall good pharmacokinetic profile.
Chemical Information
-
CAS No. 339103-05-8
-
Appearance Solid
-
Molecular Weight 292.12
-
Formula C13H7Cl2N3O
-
Color White to off-white
-
SMILES
ClC1=CC(Cl)=C(C2=NC(C3=CC=CC=N3)=NO2)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Cell Death Dis
CRLF1 bridges AKT and mTORC2 through SIN1 to inhibit pyroptosis and enhance chemo-resistance in ovarian cancer. [Abstract]2024 Sep 10;15(9):662. PMID: 39256356 -
JY-2 purchased from MedChemExpress. Usage Cited in: Aging Cell. 2026 Jul;25(7):e70623.
JY-2 (0.01 μM; 12 h; and then treated with 0.05μM triptolide for an additional 24h) partially restored mitochondrial network continuity and reduced fragmented structures in KGN cells.
JY-2 purchased from MedChemExpress. Usage Cited in: Aging Cell. 2026 Jul;25(7):e70623.
JY-2 (0.01 μM; 12 h; and then treated with 0.05μM triptolide for an additional 24 h) reversed these functional defects in the POI cells by increasing ATP levels in KGN cells.
JY-2 purchased from MedChemExpress. Usage Cited in: Aging Cell. 2026 Jul;25(7):e70623.
JY-2 (0.01 μM; 12 h; and then treated with 0.05μM triptolide for an additional 24 h) reversed MMP levels in KGN cells.
JY-2 purchased from MedChemExpress. Usage Cited in: Aging Cell. 2026 Jul;25(7):e70623.
JY-2 (0.01 μM; 12 h; and then treated with 0.05μM triptolide for an additional 24 h) markedly upregulated p‐FOXO3 expression in premature ovarian insufficiency (POI) cells.
-
Int J Chron Obstruct Pulmon Dis
Azithromycin Mitigates Tobacco Smoke-Induced Lung Senescence by Modulating the FOXO3A/CCND1 Signaling Pathway. [Abstract]2025 Nov 11:20:3631-3645. PMID: 41244262
JY-2 purchased from MedChemExpress. Usage Cited in: Int J Chron Obstruct Pulmon Dis. 2025 Nov 11:20:3631-3645. [Abstract]
JY-2 (20, 40, 60, 80, 100 μM; 12, 24, 36 h) did not significantly affect cell viability in BEAS-2B cells.
JY-2 purchased from MedChemExpress. Usage Cited in: Int J Chron Obstruct Pulmon Dis. 2025 Nov 11:20:3631-3645. [Abstract]
JY-2 (40 μM; 24 h) increased the percentage of SA-β-gal positive cells in BEAS-2B cells.
JY-2 purchased from MedChemExpress. Usage Cited in: Int J Chron Obstruct Pulmon Dis. 2025 Nov 11:20:3631-3645. [Abstract]
JY-2 (40 μM; 24 h) increased the protein expression of CCND1, P21, P53, but decreased the protein expression of FOXO3A in BEAS-2B cells.
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (342.33 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Nuclear Protein Extraction (High-Salt/Hypotonic Fractionation)
The high-salt/hypotonic fractionation method for nuclear protein extraction is based on the differential solubility of cellular components. Cytoplasmic proteins are extracted first using a hypotonic buffer that causes cell swelling and membrane rupture, followed by centrifugation to separate the cytoplasmic supernatant from the nuclear pellet. The nuclear pellet is then subjected to high-salt extraction (e. g. , 0. 4 M (NH4)2SO4 or 1 M NaCl) to solubilize tightly bound nuclear matrix proteins, including transcription factors, histones, and structural proteins associated with chromatin and the nuclear scaffold. This approach allows for the isolation of both soluble cytoplasmic proteins and salt-resistant nuclear proteins while minimizing cross-contamination.
-
Dual Luciferin reporter gene assay
Luciferin reporter gene assay is a reporting system to detect the activity of Firefly Luciferase using luciferin as a substrate, which is often used in the research of miRNA target gene verification and promoter transcriptive activity regulation. Dual luciferase usually refers to Firefly luciferase and Renilla luciferase.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.4233 mL | 17.1163 mL | 34.2325 mL | 85.5813 mL |
| 5 mM | 0.6847 mL | 3.4233 mL | 6.8465 mL | 17.1163 mL | |
| 10 mM | 0.3423 mL | 1.7116 mL | 3.4233 mL | 8.5581 mL | |
| 15 mM | 0.2282 mL | 1.1411 mL | 2.2822 mL | 5.7054 mL | |
| 20 mM | 0.1712 mL | 0.8558 mL | 1.7116 mL | 4.2791 mL | |
| 25 mM | 0.1369 mL | 0.6847 mL | 1.3693 mL | 3.4233 mL | |
| 30 mM | 0.1141 mL | 0.5705 mL | 1.1411 mL | 2.8527 mL | |
| 40 mM | 0.0856 mL | 0.4279 mL | 0.8558 mL | 2.1395 mL | |
| 50 mM | 0.0685 mL | 0.3423 mL | 0.6847 mL | 1.7116 mL | |
| 60 mM | 0.0571 mL | 0.2853 mL | 0.5705 mL | 1.4264 mL | |
| 80 mM | 0.0428 mL | 0.2140 mL | 0.4279 mL | 1.0698 mL | |
| 100 mM | 0.0342 mL | 0.1712 mL | 0.3423 mL | 0.8558 mL |
JY-2 Related Classifications
HY-153347 Related Classifications
Powered by Bioz